Skip to main content

Market Overview

UPDATE: Goldman Sachs Downgrades Charles River Laboratories on RMS Guidance Risk

Share:

In a report published Tuesday, Goldman Sachs analyst Robert P. Jones downgraded the rating on Charles River Laboratories (NYSE: CRL) from Neutral to Sell, and lowered the price target from $44.00 to $38.00.

In the report, Goldman Sachs noted, “We downgrade CRL to Sell as we see risk to guidance for RMS (Research Models) constant currency growth of 4%-6% and see little upside to PCS (Preclinical Services). We see 12% downside to our new $38, 12-month price target vs. 4% downside for our CRO coverage. On PCS, recent results and channel checks indicate still subdued early-stage spend and excess capacity as pharma prioritizes late-stage pipelines. For RMS, we estimate (excluding recent acquisitions) sales declined by 2.5% on a constant currency basis, suggesting flat volume growth. All in, we await a broader rebound in Preclinical demand and downgrade CRL as we see little valuation support.”

Charles River Laboratories closed on Monday at $43.21.

Latest Ratings for CRL

DateFirmActionFromTo
Feb 2021Morgan StanleyMaintainsOverweight
Feb 2021Morgan StanleyMaintainsOverweight
Feb 2021Truist SecuritiesMaintainsBuy

View More Analyst Ratings for CRL
View the Latest Analyst Ratings

 

Related Articles (CRL)

View Comments and Join the Discussion!

Posted-In: Goldman Sachs Robert P. JonesAnalyst Color Downgrades Analyst Ratings

Latest Ratings

StockFirmActionPT
GDWolfe ResearchDowngrades
QRTEAB of A SecuritiesInitiates Coverage On
ABB of A SecuritiesDowngrades42.0
VCTRB of A SecuritiesUpgrades32.0
BSIGB of A SecuritiesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com